Pamela Vo
VP, HEOR
Expertise:
Pamela Vo brings over 18 years of HEOR experience in the pharmaceutical industry, showcasing a history of strategically translating ideas into impactful outcomes. She boasts a proven track record of peer-reviewed publications, significant achievements in market access and reimbursement, regulatory approvals, and successful clinical product adoption. Her expertise spans multiple therapeutic areas across the United States and international landscapes. Notably, Vo’s most recent position was as the Global HEOR & Access Evidence Executive Director at Novartis.
Prior to her tenure at Novartis, Vo held roles such as Worldwide HEOR Director within the Global Patient Access division at Novartis, and various leadership positions at Lundbeck and Abbott/AbbVie, where she managed diverse healthcare portfolios.
Vo holds a Doctor of Pharmacy degree and a Master of Pharmacoeconomics and Policy degree. She recently obtained certification in Immuno-Oncology from Harvard Medical School HMX Pro. Currently based in Switzerland, Vo looks forward to expanding EVERSANA’s scientific expertise across Europe, the U.S., and beyond.
Articles by Pamela Vo
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving the quality and transparency of evidence. The framework has been updated to include guidance on external validity bias and […]
The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA
Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for market access and health technology assessment (HTA) submissions. The article delves into the mission of the JCA and the […]
Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft
On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the JCA process within the framework of the Health Technology Assessment Regulation (HTAR). By the April 2, 2024, deadline, 129 […]
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how […]